

14th August, 2026

To,

**The Corporate Relationship Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Scrip Code: 539523

**National Stock Exchange of India
Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.

Scrip Symbol: ALKEM

Sub: Outcome of the Board Meeting held on 14th August, 2026

Dear Sir(s)/ Madam,

This is in reference to our earlier intimation dated 21st July, 2026, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 14th August, 2026 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026.

The Board of Directors at its meeting held today, i.e. 14th August, 2026 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01:40 p.m.

The above information is also available on the website of the Company at www.alkemlabs.com

Kindly take the same on record.

Sincerely,
For Alkem Laboratories Limited



Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED
FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its associate for the quarter ended June 30, 2026 ("the Statement") which includes the branch of the Group located at Nepal, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial information / financial results of four subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results reflect total revenues of Rs. 2,945.1 million for the quarter ended June 30, 2026, total net profit after tax of Rs. 47.8 million for the quarter ended June 30, 2026 and total comprehensive income of Rs. 66.2 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information / financial results of twenty subsidiaries which have not been reviewed by their auditors, whose financial information / financial results reflect total revenue of Rs. 2,261.9 million for the quarter ended June 30, 2026, total net loss after tax of Rs. 100.6 million for the quarter ended June 30, 2026 and total comprehensive income of Rs. (82.7) million for the quarter ended June 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 5.1 million for the quarter ended June 30, 2026 and total comprehensive income of Rs. (5.1) million for the quarter ended June 30, 2026, as considered in the Statement, in respect of one associate, based on their interim financial information which have not been reviewed by their auditor. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.



For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: 26046930IVZRYZ3789)

Place: Mumbai
Date: August 14, 2026

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

S.N.	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings S.a.r.l.
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Private Limited, India	Subsidiary
11	Indchemie Health Specialties Private Limited, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation, India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alkem Medtech Ortho Private Limited (w.e.f 16 April 2025)	Wholly Owned Subsidiary of Alkem Medtech Private Limited
30	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
31	Alkem Wellness Limited	Wholly Owned Subsidiary
32	Adroit Biomed Limited, India (w.e.f 23 April 2025)	Wholly Owned Subsidiary
33	Alkem Pharmaceuticals Scientific Office FZ LLC, Dubai (incorporated on 4 February 2026)	Wholly Owned Subsidiary
34	Alkem Pharma Trading FZCO, Dubai (incorporated on 27 March 2026)	Wholly Owned Subsidiary
35	Haystack Analytics Private Limited	Associate

h.
e

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Consolidated Financial Results for the Quarter ended 30 June 2026

Particulars	Quarter ended			Year ended
	30.06.2026 Unaudited	31.03.2026 Unaudited (Refer Note 2)	30.06.2025 Unaudited	31.03.2026 Audited
1 Income				
(a) Revenue from Operations	37,401.5	36,033.2	33,711.4	147,122.7
(b) Other Income	1,527.5	2,000.7	1,364.9	5,833.5
Total Income	38,929.0	38,033.9	35,076.3	152,956.2
2 Expenses				
(a) Cost of materials consumed	9,100.2	8,949.4	8,271.1	35,653.9
(b) Purchases of stock-in-trade	3,659.9	4,977.7	3,972.0	16,945.0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(747.4)	(1,448.4)	(531.5)	(1,671.2)
(d) Employee benefits expense	8,089.0	7,121.0	6,932.5	28,371.1
(e) Finance costs	466.2	538.8	297.8	1,607.8
(f) Depreciation and amortisation expense	1,001.9	1,057.6	876.8	3,820.6
(g) Other expenses	9,639.3	11,259.6	7,676.8	37,771.8
Total Expenses	31,209.1	32,455.7	27,495.5	122,499.0
3 Profit before exceptional items and tax (1) - (2)	7,719.9	5,578.2	7,580.8	30,457.2
4 Exceptional items (refer note 3)	-	(1,349.7)	129.3	(1,748.3)
5 Profit before tax (3) + (4)	7,719.9	4,228.5	7,710.1	28,708.9
6 Tax expense / (credit) (Refer note 4)				
(a) Current tax	2,320.6	1,216.3	1,411.1	6,196.6
(b) Deferred tax	184.4	495.4	(384.2)	(1,019.0)
Total Tax Expense (a + b)	2,505.0	1,711.7	1,026.9	5,177.6
7 Share in loss after tax of associate	(5.1)	(5.7)	(4.1)	(19.7)
8 Profit for the period (5) - (6) + (7)	5,209.8	2,511.1	6,679.1	23,511.6
9 Other Comprehensive Income/(Loss) (net of tax)				
(a) (i) Items that will not be reclassified to profit or loss	(25.4)	354.6	(47.6)	120.9
(ii) Income tax relating to items that will not be reclassified to profit or loss	8.4	(118.4)	2.9	(38.1)
(b) (i) Items that will be reclassified to profit or loss	45.8	916.5	65.5	1,755.1
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive Income/(Loss) (net of tax)	28.8	1,152.7	20.8	1,837.9
10 Total Comprehensive Income for the period (8) + (9)	5,238.6	3,663.8	6,699.9	25,349.5
11 Profit attributable to				
a) Owners of the Company	5,199.6	2,364.6	6,642.6	23,018.0
b) Non-Controlling Interest	10.2	146.5	36.5	493.6
12 Other Comprehensive Income/(Loss) attributable to				
a) Owners of the Company	29.0	1,133.1	23.1	1,823.8
b) Non-Controlling Interest	(0.2)	19.6	(2.3)	14.1
13 Total Comprehensive Income attributable to				
a) Owners of the Company	5,228.5	3,497.7	6,665.7	24,841.8
b) Non-Controlling Interest	10.1	166.1	34.2	507.7
14 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
15 Other Equity				137,961.9
16 Earnings Per Share (not annualised for the periods) (face value of ₹ 2/- each)				
(a) Basic (₹)	43.49	19.77	55.56	192.51
(b) Diluted (₹)	43.49	19.77	55.56	192.51

Notes to the Consolidated Financial results:

1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.

2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 13 August 2026 and subsequently approved by the Board of Directors at its meeting held on 14 August 2026. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2026.

The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

3 Exceptional items includes:

1) During the quarter and year ended 31 March 2026, the Parent Company reviewed its investments in real estate; where recoverability was subject to uncertainties. Accordingly, management reassessed the carrying value of such investments and recognised a provision for impairment amounting to ₹ 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026.

2) During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Parent Company and its Indian subsidiaries assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Parent Company and its Indian subsidiaries have recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to ₹ 602.7 million in the quarter ended 31 March 2026 and ₹ 1,130.6 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results.

3) The Group sold its Indore manufacturing facility in the quarter ended 30 June 2025. The resulting gain amounting to ₹142.9 million was classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2026 and year ended 31 March 2026.


4 During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate for the quarter and year ended 31 March 2026. Subsequently in the current quarter tax expense has been recognized based on the enacted tax rates applicable under the new regime.

5 The Group, through Alkem Medtech Private Limited, its wholly owned subsidiary, has acquired a majority stake in the equity share capital of Occlutech Holding AG, Switzerland, on 16 July 2026. The acquisition was completed subsequent to the end of the reporting quarter and, accordingly, has no impact on the consolidated financial results for the quarter ended 30 June 2026.

6 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.



By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 14 August 2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal, for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN:260469300FKKZK7439)

Place: Mumbai
Date: August 14, 2026

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter ended 30 June 2026

(₹ in Million except per share data)				
	Particulars	Quarter ended		Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Unaudited) (Refer Note 2)	31.03.2026 (Unaudited) (Audited)
	Continuing Operations			
1	Income			
	(a) Revenue from Operations	26,677.3	22,584.4	23,721.7
	(b) Other Income	1,366.2	2,056.9	1,165.8
	Total Income	28,043.5	24,641.3	24,887.5
2	Expenses			
	(a) Cost of materials consumed	6,728.8	6,588.6	6,153.3
	(b) Purchases of stock-in-trade	1,466.6	1,075.0	835.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(634.9)	(666.7)	79.3
	(d) Employee benefits expense	5,474.7	4,668.6	4,697.4
	(e) Finance costs	175.2	162.4	127.9
	(f) Depreciation and amortisation expenses	572.2	781.7	588.9
	(g) Other expenses	6,276.7	7,478.7	5,751.8
	Total Expenses	20,059.3	20,088.3	18,233.7
3	Profit before exceptional items and tax from continuing operations (1) - (2)	7,984.2	4,553.0	6,653.8
4	Exceptional items (Refer note 4)	-	(1,192.1)	142.9
5	Profit before tax from continuing operations (3) + (4)	7,984.2	3,360.9	6,796.7
6	Tax expense / (credit) (Refer note 5)			
	(a) Current tax	2,077.4	747.1	1,093.4
	(b) Deferred tax	207.0	443.2	(519.3)
	Total Tax expense (a + b)	2,284.4	1,190.3	574.1
7	Profit for the period after tax from continuing operations (5 - 6)	5,699.8	2,170.6	6,222.6
	Discontinued operations (Refer note 3)			
	Profit before tax from discontinued operations	-	-	521.0
	Tax expense of discontinued operations	-	-	182.0
8	Profit from discontinued operations (after tax)	-	-	339.0
9	Profit for the period (7) + (8)	5,699.8	2,170.6	6,561.6
10	Other Comprehensive Income/ (loss) (net of tax)			
	I. In respect of continuing operations:			
	(a) (i) Items that will not be reclassified to profit or loss	(34.2)	275.0	(31.4)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	8.6	(90.0)	11.0
	(b) (i) Items that will be reclassified to profit or loss	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-
	II. In respect of discontinued operations:			
	(a) (i) Items that will not be reclassified to profit or loss	-	-	(1.7)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	0.6
	(b) (i) Items that will be reclassified to profit or loss	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-
	Total Other Comprehensive Income/(loss) (net of tax)	(25.6)	185.0	(21.5)
11	Total Comprehensive Income for the period (9) + (10)	5,674.2	2,355.6	6,540.1
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1
13	Other Equity			139,748.5
14	Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)			
	(a) Basic (₹)	47.67	18.16	52.04
	(b) Diluted (₹)	47.67	18.16	52.04
	Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)			
	(a) Basic (₹)	-	-	2.84
	(b) Diluted (₹)	-	-	2.84
	Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)			
	(a) Basic (₹)	47.67	18.16	54.88
	(b) Diluted (₹)	47.67	18.16	54.88

Notes to the Standalone Financial results:

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 13 August 2026 and subsequently approved by the Board of Directors at its meeting held on 14 August 2026. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2026.

The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

- 3 The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited.

During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

Key financial information of Discontinued Operations:

Particulars	Quarter ended			(₹ in Million)
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
Total income	-	-	3,558.2	9,181.0
Total expenses	-	-	3,037.2	7,690.5
Profit before tax	-	-	521.0	1,490.5
Total tax expense	-	-	182.0	520.8
Net profit for the period after tax	-	-	339.0	969.7

- 4 Exceptional items include:

1) During the quarter and year ended 31 March 2026, the Company reviewed its investments in real estate; where recoverability was subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to ₹ 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026.


2) During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Company recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to ₹ 445.1 million in the quarter ended 31 March 2026 and of ₹ 826.8 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results.

3) The Company sold its Indore manufacturing facility in the quarter ended 30 June 2025. The resulting gain (arising out of reversal of impairment loss) amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2025 and year ended 31 March 2026.

- 5 During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, inter alia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company had decided to opt for the new tax regime from financial year 2026 - 27. Consequently, deferred tax had been recognised at the substantially enacted rate as at 31 March 2026. Subsequently in the current quarter tax expense has been recognized based on the enacted tax rates applicable under the new regime.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai
Date: 14 August 2026

By Order of the Board
For Alkem Laboratories Limited


B.N. Singh
Executive Chairman
DIN: 00760310

Press Release

Alkem reports 11% revenue growth in Q1FY27

Mumbai, August 14, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today.

Q1FY27 Key Financial Metrics



Commenting on the results, Mr. Sandeep Singh, MD of Alkem, said, “We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging. At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses. We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner.”

Q1 FY27 Key Financial Highlights

- Total Revenue from Operations was ₹37,402 million, with YoY growth of 10.9%.
 - India sales were ₹24,978 million, YoY growth of 10.3%.
 - International sales were ₹12,223 million, with YoY growth of 16.0%.
- EBITDA at ₹7,661 million, resulted in an EBITDA margin of 20.5%, a growth of 3.7% YoY.
- R&D expenses for Q1 FY27 were ₹1,502 million, or 4.0% of total revenue from operations, vs. ₹1,184 million in Q1 FY26 at 3.5% of total revenue from operations.
- Profit before tax (before exceptional item) was ₹7, 720 million, YoY growth of 1.8%.
- Net Profit (after Non-Controlling interest) was ₹5,200 million, YoY de-growth of 21.7%.

Q1FY27 Operational Highlights

Domestic Business Key Highlights

- The contribution of domestic sales to total sales was 67.1% vs. 68.2% in Q1 FY26.
- According to IQVIA (SSA) data, for Q1 FY27:
 - The Company registered a growth of 13.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 12.2%, 100 bps outperformance.
 - Acute segment reported growth of 12.3% vs IPM which grew by 10.1%, 220 bps outperformance.

- Chronic segment reported growth of 17.9% vs. IPM which grew by 15.4%, 250 bps outperformance.
- We have outperformed IPM in seven key focused therapies: Anti-infectives grew by ~1.1X; Gastro-intestinal grew by ~1.2X, VMN ~1.4X, Pain ~1.8X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~1.6X.

International Business Key Highlights

- US sales were ₹7,439 million, YoY growth of 6.5%.
- US business sales contributed 20.0% to total sales in Q1 FY27 vs. 21.0% in Q1 FY26.
- Non-US sales were ₹4,785 million, YoY growth of 34.5%.
- Non-US business sales contributed 12.9% to total sales in Q1 FY27 vs. 10.8% in Q1 FY26.
- During Q1 FY27, for the US market, the Company received 05 ANDAs approvals (including 01 tentative approval).

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Apr-26	Official Action Indicated (OAI) in Aug 2026.
Taloja R&D (India)	Bioequivalence Centre	Apr-26	No observation received.
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	EIR Received in Oct 2025

About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50+ years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 20 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, Europe and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organization’s values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

Contact

Investors:	Media:
Purvi Shah / Dishant Doshi	Isha Trivedi / Richa Sinari
+91 84337 00890 / 99201 56882	+91 98925 90003 / 98201 84988
purvi.shah@alkem.com / dishant.doshi@alkem.com	alkemcorpcomm@alkem.com

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Invite for Q1FY27 Conference Call at 4.30 pm IST, August 14, 2026

Mumbai, July 27, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Friday, August 14, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q1FY27 financial results. The call will follow the announcement of the Company's Q1FY27 financial results on Friday, August 14, 2026.

Alkem Laboratories Ltd. will be represented on the call by:

Mr. Sandeep Singh - MD
Mr. Nitin Agrawal – CFO

Motilal Oswal Securities Ltd will host the call.

Details of the conference call are as follows

Time	4:30 pm IST (GMT + 5:30) on Friday, August 14, 2026.
-------------	--

Dial in Details

India	+91 22 6280 1149 / +91 22 7115 8050
--------------	-------------------------------------

International Toll-Free

USA	1 866 746 2133	UK	0 808 101 1573
Singapore	800 101 2045	Hong Kong	800 964 448

Express Join with Diamond Pass

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6179880&linkSecurityString=34f8c9ec58>

You are requested to dial in 10 minutes ahead of the scheduled start time.

Purvi Shah / Isha Trivedi

Investor Relations / Media
Alkem Laboratories Ltd.
Mobile: +91 84337 00890 / 98925 90003
Tel.: +91 22 3982 9999 Ext: 9447
E-mail: purvi.shah@alkem.com/
isha.trivedi@alkem.com

Tushar Manudhane

Institutional Research Analyst - Healthcare
Motilal Oswal Securities Ltd.
Tel.: +91 22 6129 1536 / +91 82911 38039
E-mail: Tushar.Manudhane@motilaloswal.com

Alkem Laboratories Ltd.

Q1 FY27 Results Presentation

14th August 2026



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

CONTENTS



Company's Financial Performance



Business Updates – Q1 FY27



Company overview and journey so far

Q1 FY27 Performance at Glance

Total Revenue from Operations

₹37,402 Mn

 **+10.9% YoY Growth**

EBITDA / Margin

₹7,661 Mn / 20.5%

 **+3.7% YoY Growth**

PAT¹ / Margin

₹5,200 Mn / 13.9%

 **-21.7% YoY Growth**

Geographic-wise Break-Up

**Domestic
Business**

67.1%

**International
Business**

32.9%

Salient Numbers

₹57.64 Bn

Net Cash as of 30th June 2026

₹1,502 Mn

R&D spend for Q1 FY27

100 bps

Outperformance in the domestic
market vs. IPM

4.0%

R&D spend as % of sales during the
quarter

1. PAT: Profit after Non Controlling Interest

Q1 FY27 – P&L Highlights

Particulars	Q1FY27	Q1FY26	YoY growth	Q4FY26	QoQ growth
Revenue from Operations	37,402	33,711	10.9%	36,033	3.8%
Gross Profit	25,389	22,000	15.4%	23,555	7.8%
Gross Profit Margin	67.9%	65.3%		65.4%	
EBITDA	7,661	7,391	3.7%	5,174	48.1%
EBITDA Margin	20.5%	21.9%		14.4%	
PBT (before exceptional item)	7,720	7,581	1.8%	5,578	38.4%
Exceptional item	-	129		(1,350)	
PBT (after exceptional item)	7,720	7,710	0.1%	4,229	82.6%
PAT (after Non-Controlling Interest)	5,200	6,643	-21.7%	2,365	119.9%
PAT Margin	13.9%	19.7%		6.6%	
EPS (₹ / share)	43.5	55.6	-21.7%	19.8	119.9%

CONTENTS



Company's Financial Performance




Business Updates – Q1 FY27



Company overview and journey so far

Domestic Business Performance


**Q1 FY27 sales of ₹24,978 Mn
(10.3% YoY growth)**



- Domestic business revenue grew by 10.3% YoY to ₹24,978 Mn from ₹ 22,650 Mn during the same period last year.
- Domestic revenue contributed 67.1% to total sales in Q1 FY27 vs. 68.2% in Q1 FY26.
- According to IQVIA (SSA) data, for Q1 FY27:
 - The Company registered a growth of 13.2% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 12.2%.
 - We've grown faster than the market in seven of IPM's key therapy areas.

Alkem has delivered a strong performance in Q1 FY27, outpacing the market growth in key focus therapies

Outpaced the market by 100 bps, delivering 13.2% growth vs. 12.2% for IPM



Value Growth

■ IPM Sales Growth YoY ■ Alkem Sales Growth YoY


Source: Market data as per IQVIA SSA Qtr. Jun'26

Outperformance in 7 of the key IPM focus therapies

Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
 Anti Infectives	7.9% 6.9%	13.3% ↑ +0.1%	1 ↔
 Gastro Intestinal	12.2% 10.2%	7.9% ↑ +0.1%	4 ↔
 VMN	21.4% 15.1%	6.8% ↑ +0.4%	2 ↔
 Pain / Analgesics	20.2% 11.5%	5.6% ↑ +0.4%	3 ↔
 Anti Diabetic	21.1% 15.5%	2.3% ↑ +0.1%	13 ↑ +1
 Neuro / CNS	8.7% 12.0%	2.4% ↓ -0.1%	8 ↔
 Respiratory	16.8% 10.5%	1.5% ↑ +0.1%	14 ↔
 Derma	16.5% 10.3%	1.6% ↑ +0.1%	19 ↔


15+ years of unmatched leadership in the Anti-Infectives therapy

Q1 FY27 US Business sales of ₹7,439 Mn (6.5% YoY growth)



- US business revenue grew by 6.5% YoY to ₹7,439 Mn from ₹ 6,982 Mn during the same period last year.
- US revenue contributed 20.0% to total sales in Q1 FY27.
- During the Q1 FY27, the Company received 05 ANDAs approvals (including 01 tentative approvals).


US Market Filing and approvals status



As of June 30, 2026, the Company has **filed 192 ANDAs, 2 NDAs and 1 BLA** and has **received 170 ANDAs approvals** (including 18 tentative approvals) **and 2 NDAs approvals**.


Non-US Business Performance

**Q1 FY27 sales of ₹4,785 Mn
(34.5% YoY growth)**



- Non-US business revenue grew by 34.5% YoY to ₹4,785 Mn from ₹ 3,556 Mn during the same period last year.
- Non-US revenue contributed 12.9% to total sales in Q1 FY27.
- The Non-US business growth was driven by double-digit growth across key markets.

Shareholding Pattern as on June 30, 2026



Promoter & Promoter Group
 Institution
 Non-Institution

BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	665,894
Free Float MCap (Rs in Mn)	334,944
Industry	Pharmaceuticals

**Share Price - Rs 5,570 from NSE as of 30th June 2026*

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

CONTENTS



Company's Financial Performance



Business Updates – Q1 FY27



Company overview and journey so far

Alkem Laboratories at Glance (FY26)



Market Leadership

#3

Rank in
Prescriptions¹

#6

Rank by value in
IPM²

Leading Player

In the Trade
Generics segment

Top 3

Player in 4 out of top
7 largest IPM's TAs²



Scale

₹1,47,123 Mn

Total Revenue³

67.8%


Domestic Revenue

17

Brand families worth
₹1000 Mn+²

14,500+

Field force⁴



Profitability

65.4%

Gross Profit
Margin

20.4%

EBITDA Margin

15.6%

PAT Margin

29.6%

ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Feb'26; 2. Market data as per IQVIA SSA MAT Mar'26; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31st March 2026

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

#2 'PAN'

Biggest Brand family in the IPM

15 Brands

in the IPM Top 300 ranks

36 Brands

Among the Top 3 ranks in their CVM¹ (Brands > ₹250 Mn)

Building large brand families defines our identity...

Brand Families	MAT Mar'21	MAT Mar'26	CAGR (5 Yrs.)
> ₹10 Bn	0	1	15.2%
> ₹5 Bn	1	1	12.4%
> ₹1.5 Bn	5	12	12.4%
> ₹500 Mn	15	17	11.2%

Brand family > ₹5 Bn

PAN **CLAVAM**

Brand family > ₹1.5 Bn

















50+ years of Alkem journey – a snapshot.



Alkem & key subsidiaries

THANK YOU

For any queries, contact:

Purvi Shah / Dishant Doshi

Mobile: +91 84337 00890 / 99201 56882

E-mail: purvi.shah@alkem.com / dishant.doshi@alkem.com

Stay updated on     

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.